Recent advances have resulted in more precise and effective treatments with fewer side effects
Radiation therapy (or radiotherapy) and surgery are the two main treatments available for curing solid tumour malignancies. Radiation therapy uses high-energy ionising radiation to destroy the DNA of cancer cells, and can be used to cure cancers, either alone or in conjunction with surgery or chemotherapy. According to the available evidence, one in two patients with cancer in Australia would benefit from receiving radiation therapy as part of their treatment.1 In cases of incurable disease, radiotherapy relieves distressing symptoms, such as pain, in two of three patients.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Barton MB, Jacob S, Shafiq J, et al. Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol 2014; 112: 140-144.
- 2. Royal Australian and New Zealand College of Radiologists. National Strategic Plan for Radiation Oncology 2012–2022. An executive summary. Sydney: RANZCR, 2012. http://www.ranzcr.edu.au/documents-download/document-library-9/document-library-14/3906-an-executive-summary-tripartite-national-strategicy-plan-for-radiation-oncology-2012-2022 (accessed Sep 2015).
- 3. Royal Australian and New Zealand College of Radiologists, Faculty of Radiation Oncology. Position papers on techniques and technologies in radiation oncology. 2013 Horizon Scan (Australia and New Zealand). http://www.ranzcr.edu.au/resources/consumers/764-radiotherapy-technologies (accessed Sep 2015).
- 4. Yong JH, Beca J, O’Sullivan B, et al. Cost-effectiveness of intensity-modulated radiotherapy in oropharyngeal cancer. Clin Oncol (R Coll Radiol) 2012; 24: 532-538.
- 5. Nutting C, Morden J, Harrington K, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancers (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011; 12: 127-136.
- 6. Beadle BM, Liao KP, Elting LS, et al. Improved survival using intensity-modulated radiation therapy in head and neck cancers: a SEER-Medicare analysis. Cancer 2014; 120; 702-710.
- 7. Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 2013; 31: 1384-1390.
- 8. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013; 14: e28-e37.
- 9. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303: 1070-1076.
- 10. Guckenberger M, Mantel F, Gerszten P, et al. Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis. Radiat Oncol 2014; 9: 226.
- 11. Jang WI, Kim MS, Bae SH, et al. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol 2013; 8: 250.
- 12. World Health Organization. Cancer. Fact sheet no. 297 [media release]. Feb 2015. http://www.who.int/mediacentre/factsheets/fs297/en/ (accessed Sep 2015).
- 13. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009; 27: 1572-1578.
- 14. Gabriel G, Delaney G, Barton M. The effect of travel distance on radiotherapy utilization in NSW and ACT. Radiother Oncol 2015; Aug 1 [Epub ahead of print]. doi: 10.1016/j.radonc.2015.07.031.
- 15. Christie DR, Sharpley CF, Bitsika V. Why do patients regret their prostate cancer treatment? A systematic review of regret after treatment for localized prostate cancer. Psychooncology 2015; 4: 1002-1011.
No relevant disclosures.